search

Active clinical trials for "Lymphoma, Extranodal NK-T-Cell"

Results 141-150 of 154

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

LymphomaExtranodal NK-T-Cell

This study was conducted to evaluate the complete response rate of avelumab in patients with NK / T-cell lymphoma besides relapsed or refractory stage lymphoma.

Unknown status35 enrollment criteria

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Extranodal NK/T-cell LymphomaNasal Type

The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).

Unknown status15 enrollment criteria

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the...

Extranodal NK/T-cell LymphomaNasal Type

This is a multicentre, open-label, single-arm, phase I/II clinical study to evaluate the safety, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with pegaspargase in patients with extranodal natural killer/T-cell lymphoma, nasal type (NKTCL).

Unknown status24 enrollment criteria

Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX...

Lymphoma,Non-Hodgkin Lymphoma,1 more

This study is to make sure whether reduced-dose radiation treatment is sufficient to control the disease in patients with early-staged extranodal nasal-type NK/T-cell lymphoma, who have got complete remission tumor after chemotherapy in a new and more effective asparaginase-based GELOX regimen

Unknown status11 enrollment criteria

Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

Extranodal NK/T-cell LymphomaNasal Type

The purpose of this study is to evaluate the efficacy and safety of avastin combined with gemcitabine, oxaliplatin, pegaspargase and dexamethasone(Avastin+ GemAOD) as first-line treatment in patients with untreated natural killer(NK)/T cell lymphoma

Unknown status25 enrollment criteria

Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma,...

Extranodal Natural Killer/T-Cell LymphomaNasal Type

The first Part: recruiting untreated ENKL patients with extensive stage I or limited stage II disease (only referring to patients with the invasion of Waldeyer's ring and cervical lymph nodes) . Patients are randomly divided into two arms, IPGDP regimen chemotherapy followed by radiotherapy or radiotherapy followed by IPGDP regimen chemotherapy. IPGDP regimen for both arms are 3 cycles. And the chemotherapy is repeated every 3 weeks.. The second part: recruiting extensive stage II ,stage III-IV, relapsed or refractory ENKL patients. Patients receive 6 cycles of IPGDP regimen chemotherapy. And the chemotherapy is repeated every 3 weeks.

Unknown status21 enrollment criteria

Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense...

Peripheral T Cell LymphomaUnspecified2 more

Peripheral T cell lymphomas comprise 10-15% of all malignant lymphomas. The prognosis is significantly worse than that of aggressive B cell lymphomas. The prospects of elderly patients are especially poor, with an estimated disease free survival of only 25% after three years. Previous phase II trials have demonstrated a significant activity of the monoclonal anti CD52 antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense CHOP-14 in patients with previously untreated peripheral T cell lymphoma.

Unknown status12 enrollment criteria

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell...

LymphomaExtranodal NK-T-Cell

The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma can predict disease progression

Unknown status8 enrollment criteria

International Extranodal NK/T-cell Lymphoma Project

Extranodal NK/T-cell LymphomaNasal Type

This study is to explore risk factors for poor progression-free survival (PFS) and overall survival (OS) in ENKTL, and establish a prognostic model for ENKTL patients treated with non-anthracycline based treatment.

Completed8 enrollment criteria

Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients...

Extranodal NK-T-Cell LymphomaNasal Type

The purpose of this study is to collect data from patients by social media and self-report on the adverse events and outcomes happened with patients with extranodal natural killer/T-cell lymphoma, nasal type, who are treated outside of clinical trials in China.

Completed5 enrollment criteria
1...141516

Need Help? Contact our team!


We'll reach out to this number within 24 hrs